This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| clopidogrel | |
|---|---|
| Name | Clopidogrel |
| Routes of administration | Oral |
| Metabolism | Hepatic (CYP enzymes) |
clopidogrel
Clopidogrel is an antiplatelet medication used to reduce the risk of thrombotic events in patients with atherothrombotic disease. It is prescribed after acute coronary syndromes, percutaneous coronary intervention, or ischemic stroke to prevent myocardial infarction and vascular death. Major clinical guidelines and organizations recommend its use alongside other cardiovascular therapies for secondary prevention.
Clopidogrel is indicated for prevention of atherothrombotic events in patients with recent myocardial infarction, recent ischemic stroke, or established peripheral arterial disease, and for use in conjunction with percutaneous coronary intervention including stent placement for acute coronary syndromes. Clinical trials involving populations across centers comparable to Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, and major consortia such as the World Health Organization and American Heart Association informed its adoption into guidelines from bodies like the European Society of Cardiology and the National Institute for Health and Care Excellence. It has been compared with other antiplatelet agents used in settings involving institutions such as Cleveland Clinic and trials sponsored by organizations like Hospital for Special Surgery and research groups at Massachusetts General Hospital.
Clopidogrel exerts its effect by irreversibly inhibiting the P2Y12 adenosine diphosphate receptor on platelets, reducing platelet aggregation in pathways studied in laboratories affiliated with Harvard Medical School, Stanford University School of Medicine, and University of Oxford. Metabolism involves hepatic cytochrome P450 enzymes including CYP2C19, CYP3A4, and others characterized in biochemical research at institutions such as National Institutes of Health and Scripps Research. Pharmacokinetic and pharmacodynamic studies published from centers like Mayo Clinic, Brigham and Women's Hospital, and University College London detail active metabolite formation, onset of action, and platelet function assays used in clinical practice at hospitals including Mount Sinai Hospital and Royal Brompton Hospital.
Common adverse effects include bleeding complications documented in registries from systems like Medicare and trials conducted across networks including Duke University Medical Center and Vanderbilt University Medical Center. Serious hemorrhagic events, gastrointestinal bleeding, and rare hematologic reactions were recorded in pharmacovigilance reports coordinated by agencies such as the Food and Drug Administration, the European Medicines Agency, and national agencies in countries represented at the World Health Organization. Safety in surgical settings is addressed in perioperative guidance from societies like the American College of Surgeons and Royal College of Surgeons.
Clopidogrel's efficacy and safety are affected by concomitant medications and substances identified in formularies at institutions like Johns Hopkins Hospital, Cleveland Clinic, and regulatory advisories from the Food and Drug Administration and European Medicines Agency. Proton pump inhibitors, some statins, and strong CYP inhibitors alter activation via enzymes characterized by research groups at Scripps Research, University of California, San Francisco, and Imperial College London. Drug interaction databases maintained by organizations such as the World Health Organization and clinical pharmacology services at Stanford Health Care summarize contraindications and monitoring recommendations endorsed by guideline committees at American College of Cardiology.
Genetic variation in CYP2C19 substantially influences metabolic activation and clinical response; landmark pharmacogenomic studies were conducted through collaborations including National Institutes of Health, Wellcome Trust, and consortia with investigators from University of Oxford, Harvard Medical School, and Vanderbilt University Medical Center. Regulatory communications about genotype-guided therapy involve agencies such as the Food and Drug Administration and professional societies including the Clinical Pharmacogenetics Implementation Consortium and the American College of Medical Genetics and Genomics. Implementation projects integrating genotyping into practice have been piloted at centers like Mayo Clinic and Geisinger Health System.
Chemists at academic and industrial laboratories including Massachusetts Institute of Technology, ETH Zurich, and pharmaceutical companies comparable to Sanofi and Bristol-Myers Squibb have described the thienopyridine scaffold and synthetic routes to produce the prodrug. Synthesis involves multi-step organic transformations, chiral centers, and scale-up methods developed in process chemistry units at firms similar to Pfizer and Novartis. Structural elucidation and analytical methods were advanced in research facilities at California Institute of Technology and University of Cambridge.
Clopidogrel's development, regulatory approval, and commercial history intersect with large clinical trials, corporate research programs, and policy decisions involving entities such as Food and Drug Administration, European Medicines Agency, and multinational pharmaceutical companies with operations like AstraZeneca and Sanofi. Its adoption into practice was shaped by landmark trials conducted at centers including Brigham and Women's Hospital, Duke University Medical Center, and international collaborations supported by organizations such as the World Health Organization and funding bodies like the Wellcome Trust. Societal debates over cost, generic availability, and guideline recommendations have involved health systems such as National Health Service and payer organizations comparable to Centers for Medicare & Medicaid Services.
Category:Antiplatelet agents